DHR · Industrials
DANAHER CORP /DE/
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Quarterly Dividend DeclarationImportance 13 · Surprise 6Danaher declared a quarterly cash dividend of USD 0.40 per share for shareholders. The dividend is payable on October 30, 2026. The shares have an ex-dividend date of September 30, 2026. The declared rate implies…
News · 2026-09-21
- Quarterly Dividend DeclarationImportance 5 · Surprise 6Danaher approved a quarterly cash dividend, according to the September 21, 2026 news digest. The digest does not report the dividend amount per share. The digest also does not specify the declaration date, record date,…
News · 2026-09-16
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Danaher reaffirmed its quarterly cash dividend at $0.40 per share. The dividend is payable on October 30, 2026. The reaffirmed rate represents an annualized dividend of $1.60 per share.
News · 2026-09-15
- Quarterly Dividend DeclarationImportance 9 · Surprise 6Danaher’s Board approved a regular quarterly cash dividend of $0.40 per common share on September 15, 2026. The dividend is payable on October 30, 2026. Shareholders must be recorded as of September 30, 2026, to…
News · 2026-09-08
- Revenue Performance and MixImportance 49 · Surprise 32Danaher reported mid-single-digit revenue growth in Q2 2026. Improved profitability was attributed to efficiency programs and portfolio optimization. Diagnostics and life-science tools were identified as key portfolio…
- End-Market Demand TrendsImportance 40 · Surprise 56The global research-use recombinant protein market is forecast to grow from $1.11 billion in 2026 to $1.55 billion by 2031, representing approximately 40% expansion. Growth is expected to be driven by expanding…
News · 2026-09-07
- Revenue Performance and MixImportance 49 · Surprise 32Danaher reported mid-single-digit revenue growth in Q2 2026. Improved profitability was attributed to efficiency programs and portfolio optimization. Diagnostics and life-science tools were identified as key portfolio…
News · 2026-09-04
- Revenue Performance and MixImportance 49 · Surprise 32Danaher reported mid-single-digit revenue growth in Q2 2026. Improved profitability was attributed to efficiency programs and portfolio optimization. Diagnostics and life-science tools were identified as key portfolio…
News · 2026-09-03
- Revenue Performance and MixImportance 49 · Surprise 32Danaher reported mid-single-digit revenue growth in Q2 2026. Improved profitability was attributed to efficiency programs and portfolio optimization. Diagnostics and life-science tools were identified as key portfolio…
News · 2026-09-02
- Revenue Performance and MixImportance 49 · Surprise 32Danaher reported mid-single-digit revenue growth in Q2 2026. Improved profitability was attributed to efficiency programs and portfolio optimization. Diagnostics and life-science tools were identified as key portfolio…
- End-Market Demand TrendsImportance 40 · Surprise 56The global research-use recombinant protein market is forecast to grow from $1.11 billion in 2026 to $1.55 billion by 2031, representing approximately 40% expansion. Growth is expected to be driven by expanding…
News · 2026-08-28
- Leadership TransitionImportance 31 · Surprise 42Danaher appointed Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026. Montgomery currently leads Danaher’s Diagnostics platform and will succeed Rainer Blair, who is retiring.…
News · 2026-08-25
- Biotechnology Demand TrendsImportance 31 · Surprise 32Danaher’s Biotechnology segment sales increased 4% in the second quarter of 2026. Growth was driven primarily by strong demand in China and improved performance in bioprocessing and medical businesses. Difficult…
News · 2026-08-24
- Revenue Performance and MixImportance 37 · Surprise 6Danaher reported $6.26 billion of revenue for the second quarter of 2026 following its July 20 earnings release. Quarterly earnings were $1.94 per share, and revenue exceeded analyst estimates. The digest provides no…
- Leadership TransitionImportance 37 · Surprise 42President and CEO Rainer Blair is scheduled to be succeeded by Julie Sawyer Montgomery on October 1, 2026. Blair sold 58,255 shares held indirectly through a trust on August 21, 2026, for approximately $12.7 million.…
News · 2026-08-22
- Revenue Performance and MixImportance 30 · Surprise 14Danaher reported quarterly revenue of $6.26 billion, up 5.5% year over year. Adjusted EPS was $1.94, exceeding the $1.85 analyst consensus by $0.09. The company surpassed both quarterly revenue and earnings…
News · 2026-08-21
- Revenue Performance and MixImportance 30 · Surprise 14Danaher reported quarterly revenue of $6.26 billion, up 5.5% year over year. Adjusted EPS was $1.94, exceeding the $1.85 analyst consensus by $0.09. The company surpassed both quarterly revenue and earnings…
News · 2026-08-20
- Revenue Performance and MixImportance 45 · Surprise 14Danaher reported second-quarter revenue of $6.26 billion, up 5.5% year over year. Second-quarter adjusted EPS was $1.94, exceeding the $1.85 analyst consensus. The digest does not provide segment-level revenue,…
- Leadership TransitionImportance 25 · Surprise 42Julie Sawyer Montgomery was appointed Danaher’s new chief executive officer. The leadership change was referenced in coverage discussing the company’s maintained guidance and strategic execution. The digest provided no…
- Guidance / OutlookImportance 17 · Surprise 24Danaher maintained its full-year guidance following the transition to a new chief executive officer. The company had previously raised its full-year adjusted earnings outlook. Third-party reporting linked renewed…
News · 2026-08-19
- Revenue Performance and MixImportance 45 · Surprise 14Danaher reported second-quarter revenue of $6.26 billion, up 5.5% year over year. Second-quarter adjusted EPS was $1.94, exceeding the $1.85 analyst consensus. The digest does not provide segment-level revenue,…
- Masimo AcquisitionImportance 28 · Surprise 42Third-party reporting identified Danaher’s acquisition of Masimo Corporation as a key strategic initiative supporting investor sentiment. The reports described strategic execution of the Masimo transaction but did not…
- Leadership TransitionImportance 25 · Surprise 42Julie Sawyer Montgomery was appointed Danaher’s new chief executive officer. The leadership change was referenced in coverage discussing the company’s maintained guidance and strategic execution. The digest provided no…
- Guidance / OutlookImportance 17 · Surprise 24Danaher maintained its full-year guidance following the transition to a new chief executive officer. The company had previously raised its full-year adjusted earnings outlook. Third-party reporting linked renewed…
News · 2026-08-18
- Revenue Performance and MixImportance 33 · Surprise 6Danaher reported quarterly revenue of approximately $6.26 billion, exceeding market expectations. Adjusted earnings per share were $1.94, above the $1.85 consensus estimate. The reported earnings beat supported a…
News · 2026-08-17
- Free Cash FlowImportance 37 · Surprise 6Danaher was reported to generate more than $4.3 billion in free cash flow. The free-cash-flow figure was presented alongside reported revenue growth of 5.50% and a $142.32 billion market capitalization. The digest did…
- Revenue Performance and MixImportance 36 · Surprise 14Danaher reported quarterly revenue of approximately $6.26 billion. Revenue was described as growing 5.50%, exceeding the materiality threshold based on the company’s $6.265 billion revenue baseline. The reported…
News · 2026-08-16
- Revenue Performance and MixImportance 12 · Surprise 6Danaher reported second-quarter revenue of approximately $6.26 billion. Quarterly earnings were $1.94 per share, exceeding analyst expectations. The reported results prompted a Moderate Buy consensus rating, although…
News · 2026-08-14
- Bioprocessing Demand and DelaysImportance 25 · Surprise 32Danaher’s bioprocessing unit missed expectations in the second quarter of 2026, weighing on connected life-sciences companies such as Bio-Rad and Sartorius. Reporting points to a potential recovery as bioprocessing…
News · 2026-08-11
- Revenue Performance and MixImportance 36 · Surprise 14Danaher beat earnings estimates in the reported period. Revenue increased 5.5% year over year. The digest did not provide segment revenue, geographic revenue, or dollar revenue figures.
News · 2026-08-10
- Revenue Performance and MixImportance 36 · Surprise 14Danaher beat earnings estimates in the reported period. Revenue increased 5.5% year over year. The digest did not provide segment revenue, geographic revenue, or dollar revenue figures.
News · 2026-08-09
- Leadership TransitionImportance 31 · Surprise 42Julie Sawyer Montgomery will become Danaher’s president and CEO in October 2026, succeeding Rainer Blair. Blair will retire from the CEO role but remain with Danaher as a senior advisor. Montgomery, who joined Danaher…
News · 2026-08-08
- Revenue Performance and MixImportance 31 · Surprise 32Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology…
News · 2026-08-07
- Revenue Performance and MixImportance 31 · Surprise 32Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology…
- Leadership TransitionImportance 31 · Surprise 42Danaher appointed Julie Sawyer Montgomery as President and CEO effective October 1, 2026. Montgomery, currently an executive vice president and leader of the Diagnostics platform, will succeed Rainer Blair, who is…
News · 2026-08-06
- Leadership TransitionImportance 31 · Surprise 42Danaher appointed Julie Sawyer Montgomery as President and CEO effective October 1, 2026. Montgomery, currently an executive vice president and leader of the Diagnostics platform, will succeed Rainer Blair, who is…
News · 2026-08-05
- Revenue Performance and MixImportance 31 · Surprise 32Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology…
- Leadership TransitionImportance 31 · Surprise 42Danaher appointed Julie Sawyer Montgomery as President and CEO effective October 1, 2026. Montgomery, currently an executive vice president and leader of the Diagnostics platform, will succeed Rainer Blair, who is…
News · 2026-08-04
- Revenue Performance and MixImportance 31 · Surprise 32Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology…
- Leadership TransitionImportance 31 · Surprise 42Danaher appointed Julie Sawyer Montgomery as President and CEO effective October 1, 2026. Montgomery, currently an executive vice president and leader of the Diagnostics platform, will succeed Rainer Blair, who is…
8-K · 2026-08-03
- Competition and Market PositionImportance 75 · Surprise 64Danaher said its Diagnostics platform has consistently gained share in attractive end markets under Julie Sawyer Montgomery’s leadership. The platform grew from approximately $6.0 billion in revenue in 2017 to…
- Revenue Performance and MixImportance 69 · Surprise 64Danaher’s Diagnostics platform grew from approximately $6.0 billion of revenue in 2017 to approximately $11.0 billion in 2026. The platform’s revenue increased by approximately $5.0 billion, or about 83%, over that…
- Leadership TransitionImportance 44 · Surprise 60Danaher appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board, effective October 1, 2026. Rainer Blair will retire on the same date and remain as a senior advisor through…
- Guidance / OutlookImportance 29 · Surprise 6Danaher reaffirmed its previously communicated third-quarter 2026 guidance. The company also reaffirmed its previously communicated full-year 2026 guidance. The August 3, 2026 leadership announcement therefore did not…
News · 2026-08-03
- Leadership TransitionImportance 44 · Surprise 60Danaher appointed Julie Sawyer Montgomery as president and chief executive officer effective October 1, 2026, succeeding retiring CEO Rainer Blair. Montgomery has led the Diagnostics platform since joining Danaher in…
- Guidance / OutlookImportance 20 · Surprise 24Danaher reaffirmed its previously communicated financial guidance for the third quarter and full year 2026. The guidance was maintained in conjunction with the October 1, 2026 CEO transition. Third-party reporting said…
News · 2026-08-02
- Guidance / OutlookImportance 20 · Surprise 24Danaher reaffirmed its previously communicated financial guidance for the third quarter and full year 2026. The guidance was maintained in conjunction with the October 1, 2026 CEO transition. Third-party reporting said…
News · 2026-07-30
- Guidance / OutlookImportance 20 · Surprise 24Danaher reaffirmed its previously communicated financial guidance for the third quarter and full year 2026. The guidance was maintained in conjunction with the October 1, 2026 CEO transition. Third-party reporting said…
News · 2026-07-29
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
- End-Market Demand TrendsImportance 17 · Surprise 24Third-party analysts cited continued weakness and underperformance in Danaher’s bioprocessing business, keeping investor sentiment subdued despite broader company results exceeding expectations. The reports indicate…
News · 2026-07-28
- Guidance / OutlookImportance 62 · Surprise 68Danaher’s third-party-reported outlook calls for Q3 2026 revenue growth of 2%–3%, reflecting a headwind in respiratory testing. The company reportedly expects high-single-digit growth in its bioprocessing business…
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
News · 2026-07-27
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
- End-Market Demand TrendsImportance 17 · Surprise 24Third-party analysts cited continued weakness and underperformance in Danaher’s bioprocessing business, keeping investor sentiment subdued despite broader company results exceeding expectations. The reports indicate…
News · 2026-07-26
- Guidance / OutlookImportance 62 · Surprise 68Danaher’s third-party-reported outlook calls for Q3 2026 revenue growth of 2%–3%, reflecting a headwind in respiratory testing. The company reportedly expects high-single-digit growth in its bioprocessing business…
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
- Revenue Performance and MixImportance 55 · Surprise 32Danaher exceeded analysts’ revenue expectations in the second quarter of 2026. The bioprocessing business underperformed, although Danaher projected high-single-digit growth for that segment. Diagnostics generated CHF…
News · 2026-07-25
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
News · 2026-07-24
- Capital AllocationImportance 58 · Surprise 42Danaher has completed more than US$4.79 billion of share repurchases. The repurchases reduced the company’s share count and were described as supporting earnings per share while revenue growth expectations slowed. The…
- Revenue Performance and MixImportance 55 · Surprise 32Danaher exceeded analysts’ revenue expectations in the second quarter of 2026. The bioprocessing business underperformed, although Danaher projected high-single-digit growth for that segment. Diagnostics generated CHF…